OCGN Ocugen Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: OCGN

Price (delayed)

$1.21

Market cap

$409.61M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.24

Enterprise value

$410.73M

?
Relative Growth: Rel. Growth: 36
Relative Strength: Rel. Strength: 22
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 22

Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Its breakthrough modifier ...

Highlights
The equity has soared by 148% QoQ but it has shrunk by 64% YoY
OCGN's quick ratio has surged by 89% since the previous quarter but it is down by 31% year-on-year
The net income fell by 25% YoY and by 6% QoQ
The EPS has declined by 14% year-on-year and by 4.3% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://ocugen.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of OCGN

OCGN stock price

How has the Ocugen stock price performed over time
Intraday
-4.72%
1 week
-11.03%
1 month
-12.95%
1 year
8.04%
YTD
-10.37%
QTD
-20.92%

Financial performance

How have Ocugen's revenue and profit performed over time
Revenue
$4.47M
Gross profit
$4.47M
Operating income
-$66.25M
Net income
-$71.67M
Gross margin
100%
Net margin
-1,605.2%
The net margin has contracted by 26% YoY and by 4.4% from the previous quarter
The net income fell by 25% YoY and by 6% QoQ
The company's operating margin fell by 18% YoY and by 4.1% QoQ
The operating income has declined by 16% year-on-year and by 5% since the previous quarter

Price vs fundamentals

How does OCGN's price correlate with its fundamentals

Growth

What is Ocugen's growth rate over time

Valuation

What is Ocugen stock price valuation
P/E
N/A
P/B
68.35
P/S
88.76
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
91.99
The EPS has declined by 14% year-on-year and by 4.3% since the previous quarter
The price to book (P/B) is 177% more than the 5-year quarterly average of 24.7
The equity has soared by 148% QoQ but it has shrunk by 64% YoY
The price to sales (P/S) is 6% less than the last 4 quarters average of 94.1

Efficiency

How efficient is Ocugen business performance
The return on assets has declined by 47% year-on-year and by 9% since the previous quarter
The return on sales has declined by 21% year-on-year and by 5% since the previous quarter
The ROIC has grown by 18% YoY but it has contracted by 9% from the previous quarter

Dividends

What is OCGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for OCGN.

Financial health

How did Ocugen financials performed over time
OCGN's total assets is 11% greater than its total liabilities
OCGN's quick ratio has surged by 89% since the previous quarter but it is down by 31% year-on-year
The current ratio has surged by 75% since the previous quarter but it has declined by 28% year-on-year
The debt to equity has surged by 187% year-on-year
The equity has soared by 148% QoQ but it has shrunk by 64% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.